CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that four abstracts have been accepted for presentation, including three oral presentations, on the 25and Annual meeting of the American Society of Gene and Cell Therapy (ASGCT) to be held in Washington, D.C., and virtually, May 16-19, 2022. The company is presenting data on its pipeline and platform technologies to support programs ongoing development.
Key Editas Medicine presentations at ASGCT include:
Preclinical data on EDIT-202 demonstrating maintained expression levels of CD16 and mbIL15, prolonged persistence in the absence of exogenous cytokines, and significantly improved anti-tumor efficacy in a live solid tumor model.
Safety data from the BRILLIANCE trial of EDIT-101 demonstrating a favorable immunogenic profile.
Preclinical data from non-human primate studies of EDIT-103, under development for the treatment of autosomal dominant rhodopsin-associated retinitis pigmentosa (RHO-adRP), demonstrating nearly 100% inactivation of genetic editing of the endogenous RHO gene and over 30% replacement protein levels.
Data demonstrating that SLEEK (Selection by Essential-gene Exon Knock-in) gene editing is an optimal strategy to obtain a robust multi-transgene knock-in for the next generation of cell therapy drugs.
“Editas Medicine is making great strides toward the clinic with our preclinical pipeline and in our efforts to develop transformative medicines for people living with serious diseases, including eye disease, hemoglobinopathies and cancer,” said Mark S. Shearman, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. “We look forward to sharing compelling data and important updates for several of our programs, including EDIT-101, EDIT-103, EDIT-202 and our gene editing method SLEEK at ASGCT later this month. -this.”
Title: Exploratory immunosafety profile of EDIT-101, a first in humans In-vivo CRISPR gene editing therapy for CEP290– Related retinal degeneration
Session date and time: Monday, May 16, 2022, 1:30 p.m. – 3:15 p.m. ET
Presentation time: 2:45 p.m. – 3:00 p.m. ET
Session title: Ongoing gene and cell therapy trials
Title: SLEEK: a method for highly efficient activation and expression of transgenic cargoes for next-generation cellular drugs
Session date and time: Wednesday, May 18, 2022, 3:45 p.m. to 5:30 p.m. ET
Presentation time: 5:00 p.m. – 5:15 p.m. ET
Session title: New Gene Editing Technologies and Applications
Title: A Mutation-Agnostic CRISPR/Cas9-Based Inactivation and Replacement Strategy for Treating Rhodopsin-Associated Autosomal Dominant Retinitis Pigmentosa
Session Date and time: Thursday, May 19, 2022, 10:15 a.m. to 12 p.m. ET
Presentation time: 10:15 a.m. – 10:30 a.m. ET
Session title: Ophthalmic and auditory diseases
Title: EDIT-202, a multiplexed CRISPR-Cas12a gene-modified iPSC-derived NK cell therapy has prolonged persistence, promotes high cytotoxicity and improves In-vivo tumor killer
Session date and time: Wednesday, May 18, 2022, 5:30 p.m. to 6:30 p.m. ET
Session title: Cancer – Targeted Cell and Gene Therapy II
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a strong portfolio of treatments for people living with critical illnesses worldwide. . Editas Medicine aims to discover, develop, manufacture and commercialize precision, sustainable and transformative genomic medicines for a broad class of diseases. For the latest scientific information and presentations, please visit www.editasmedicine.com.
This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect “, “intend”, “may”, “plan”, “potential”, “predict”, “project”, “target”, “should”, “would” and similar expressions are intended to identify the forward-looking statements, although all forward-looking statements contain these identifying words, the Company may not actually achieve the plans, intentions or expectations disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements due to a variety of factors, including: the uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company’s product candidates; the availability and timing of results from preclinical studies and clinical trials; whether the interim results of a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations regarding regulatory approvals to conduct trials or to commercialize products and the availability of sufficient funding for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure needs. These and other risks are described in greater detail under the heading “Risk Factors” included in the company’s most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission, and in other documents filed by the company. with the Securities and Exchange Commission in the future. All forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Contacts: Media Cristi Barnett (617) 401-0113 email@example.com Investors Ron Moldaver (617) 401-9052 firstname.lastname@example.org